Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
5.70
+0.08 (1.42%)
At close: Feb 6, 2026, 4:00 PM EST
5.68
-0.02 (-0.35%)
After-hours: Feb 6, 2026, 7:57 PM EST
Nuvation Bio Employees
Nuvation Bio had 291 employees as of September 30, 2025. The number of employees increased by 88 or 43.35% compared to the same quarter last year.
Employees
291
Change
88
Growth
43.35%
Revenue / Employee
$91,918
Profits / Employee
-$747,354
Market Cap
1.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Sep 30, 2021 | 58 | 30 | 107.14% |
| Jun 30, 2021 | 51 | 23 | 82.14% |
| Mar 31, 2021 | 38 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Sarepta Therapeutics | 1,372 |
| Recursion Pharmaceuticals | 800 |
| Vericel | 357 |
| Ocular Therapeutix | 274 |
| Harmony Biosciences Holdings | 268 |
| Aurinia Pharmaceuticals | 130 |
| Stoke Therapeutics | 128 |
NUVB News
- 4 days ago - Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy - Seeking Alpha
- 15 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 24 days ago - Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 25 days ago - Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - Business Wire
- 4 weeks ago - Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List - PRNewsWire
- 2 months ago - Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha